MAIER PAUL V — SEC Form 4 filings
SEC reporting owner CIK 1182615. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-15 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 3 filings — 132,802 shares, $5,917,641 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: sale of 36,387 shares @ $58.64 ($2,133,734) in Eton Pharmaceuticals, Inc., filed 2026-08-31.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | Director | 6 | — | 6 legs · 100,000 sh · $5,907,144 | 11 |
| International Stem Cell CORP (ISCO) | Director | 5 | — | 1 leg · 32,802 sh · $10,497 | 7 |
| Ambrx Biopharma, Inc. (AMAM) | Director | 1 | — | — | 3 |
Form 4 filings — MAIER PAUL V
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | International Stem Cell CORP (ISCO) | Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2026-09-15 | 4 | International Stem Cell CORP (ISCO) | Sale (S): 32,802 @ $0.32 | EDGAR |
| 2026-08-31 | 4/A | Eton Pharmaceuticals, Inc. (ETON) | Option exercise (M): 50,000 @ $3.78 · Sale (S): 36,387 @ $58.64 · Sale (S): 13,485 @ $60.21 · Sale (S): 128 @ $61.77 · Option exercise (M): 12,500 @ $7.31 · Option exercise (M): 50,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-28 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Option exercise (M): 50,000 @ $3.78 · Sale (S): 36,387 @ $58.64 · Sale (S): 13,485 @ $60.21 · Sale (S): 128 @ $61.77 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | International Stem Cell CORP (ISCO) | Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 182,584 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | International Stem Cell CORP (ISCO.OB) | Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 532,786 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | International Stem Cell CORP (ISCO.OB) | Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 361,111 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Ambrx Biopharma, Inc. (AMAM) | Disposition to issuer (D): 12,142 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2024-02-15 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1182615 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →